| US 7,556,809 B2 | ||
| Active antiangiogenic therapy | ||
| Mónica Bequet Romero, Ciudad de La Habana (Cuba); Boris Ernesto Acevedo Castro, Ciudad de La Habana (Cuba); Jorge Victor Gavilondo Cowley, Ciudad de La Habana (Cuba); Luis Enrique Fernández Molina, Ciudad de La Habana (Cuba); Omar Lopez Ocejo, Ciudad de La Habana (Cuba); Ricardo de la Caridad Silva Rodriguez, Ciudad de La Habana (Cuba); Alexis Musachio Lasa, Mariel (Cuba); Ernesto Galban Rodriguez, Ciudad de La Habana (Cuba); and Dania Marcia Vázquez Blomquist, Ciudad de La Habana (Cuba) | ||
| Assigned to Centro De Ingenieria Genetica Y Biotechnologia, Ciudad de La Habana (Cuba) | ||
| Appl. No. 10/511,384 PCT Filed Apr. 11, 2003, PCT No. PCT/CU03/00004 § 371(c)(1), (2), (4) Date Apr. 27, 2005, PCT Pub. No. WO03/086450, PCT Pub. Date Oct. 23, 2003. |
||
| Claims priority of application No. 76/02 (CU), filed on Apr. 15, 2002. | ||
| Prior Publication US 2005/0175624 A1, Aug. 11, 2005 | ||
| Int. Cl. A61K 39/095 (2006.01); A61K 39/39 (2006.01); A61K 38/18 (2006.01); A61K 38/04 (2006.01); A61K 39/395 (2006.01); C07K 4/12 (2006.01) | ||
| U.S. Cl. 424—185.1 [424/192.1; 424/193.1; 530/328; 530/399] | 2 Claims |
| 1. An immunogenic composition comprising an autologous VEGF-A polypeptide impaired for receptor activation identified as the
amino acid sequence set forth in SEQ ID NO: 21 or fragments thereof identified as the amino acid sequence set forth in SEQ
ID NO: 27 to SEQ ID NO: 36 and SEQ ID NO: 77 to SEQ ID NO: 86; and at least one of the molecules described in:
a) VEGFR2 polypeptide fragments identified as the amino acid sequence set forth in SEQ ID NO: 137 to SEQ ID NO: 146 and SEQ
ID NO: 187 to SEQ ID NO: 196;
b) VEGFR2 polypeptide fragments identified as the amino acid sequence set forth in SEQ ID NO: 137 to SEQ ID NO: 146 and SEQ
ID NO: 187 to SEQ ID NO: 196, said composition being mixed with or fused to p64K protein of Neisseria meningitides;
c) VEGFR2 polypeptide fragments identified as the amino acid sequence set forth in SEQ ID NO: 137 to SEQ ID NO: 146 and SEQ
ID NO: 187 to SEQ ID NO: 196, said composition being mixed with or noncovalently bound to very small particles (VSSP) from
complex of outer membrane proteins of Neisseria meningitides;
d) VEGFR2 polypeptide fragment identified as the amino acid sequence set forth in SEQ ID NO: 23;
e) VEGFR2 polypeptide fragment identified as the amino acid sequence set forth in SEQ ID NO: 23, said composition being mixed
with or fused to p64K protein of Neisseria meningitides;
f) VEGFR2 polypeptide fragment identified as the amino acid sequence set forth in SEQ ID NO: 23, said composition being mixed
with or from complex of outer membrane proteins of Neisseria meningitides;
g) VEGFR2 polypeptide fragment identified as VEGF-A SEQ ID NO: 25;
h) VEGFR2 polypeptide fragment identified as VEGF-A SEQ ID NO: 25, said composition being mixed with or fused to p64K protein
of Neisseria meningitides; or
i) VEGFR2 polypeptide fragment identified as VEGF-A SEQ ID NO: 25, said composition being mixed with or noncovalently bound
to very small particles (VSSP) from comples of outer membrane proteins of Neisseria meningitides;
and optionally further comprising a pharmaceutically accepted adjuvant.
|